Table 2.
In vitro studies of the developed nanocarriers loaded with CBD.
| Type of Nanocarrier | In Vitro Studies | Reference |
|---|---|---|
| Nanosuspension | Drug release | [44] |
| Nanosuspension | Drug release | [45] |
| Nanomicelles | Drug release MJ cells T-24 cells |
[46] |
| Nanomicelles | hCEc cells | [47] |
| Nanoparticles | T-24 cells UM-UC-3 cells 5637 cells SVHUC-1 cells |
[48] |
| Nanoparticles | Drug release SKOV-3 |
[49] |
| Nanoparticles | No data available | [50] |
| Nanoemulsions | No data available | [51] |
| SNEEDS | No data available | [52] |
| SNEEDS | No data available | [53] |
| Nanoemulsion | No data available | [54] |
| Nanoemulsion | No data available | [55] |
| Microemulsion | Drug release Ex vivo permeation (Franz cells) Skin-PAMPA |
[56] |
| Nanostructured lipid particles | Drug release | [57] |
| Nanovesicles | RAW264.7 cells | [58] |
| Nanovesicles | Drug release Ex vivo permeation (Franz cells) Colorectal membrane integrity |
[59] |
| Hybrid nanoparticles | Drug release L929 mouse fibroblast Water-vapor permeability |
[60] |